<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00907673</url>
  </required_header>
  <id_info>
    <org_study_id>2008-CHF-001</org_study_id>
    <nct_id>NCT00907673</nct_id>
  </id_info>
  <brief_title>The Automated Fluid Shunt (AFS)in Chronic Congestive Heart Failure</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovaShunt AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NovaShunt AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 28-week, feasibility study to investigate the safety and efficiency of the Automatic Fluid&#xD;
      Shunt in patients with chronic congestive heart failure, ascites and diuretic resistance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate safety of the Automated Fluid Shunt device during a 28-week follow-up and to evaluate its efficacy by measuring change in NT-proBNP from baseline to 16 weeks, in patients with chronic congestive heart failure, ascites and diuretic resistance.</measure>
    <time_frame>16 and 28 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the effect of AFS-treatment on functional capacity (NYHA class and 6-min. walking distance) compared from baseline to 16 and 28 weeks</measure>
    <time_frame>16 and 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine change in LV volumes and LVEF (echocardiography) compared from baseline to 16 and 28 weeks</measure>
    <time_frame>16 and 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine change in ascites, hydrothorax and leg edema (based on CT evaluation) compared from baseline to 16 and 28 weeks</measure>
    <time_frame>16 and 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine change in renal function (GFR) compared from baseline to 16 and 28 weeks</measure>
    <time_frame>16 and 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine change in quality of life based on Minnesota Living with Heart Failure Questionnaire (MLHFQ) compared from baseline to 4, 12 and 28 weeks</measure>
    <time_frame>baseline to 4, 12 and 28 week</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Congestive Heart Failure</condition>
  <condition>Ascites</condition>
  <arm_group>
    <arm_group_label>Patient condition pre-implant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Automatic Fluid Shunt System</intervention_name>
    <description>Fully implantable peritoneal catheter, bladder catheter, and pump</description>
    <arm_group_label>Patient condition pre-implant</arm_group_label>
    <other_name>AFS System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female or male patients ≥ 18 years of age&#xD;
&#xD;
          -  A clinical diagnosis of chronic congestive heart failure &gt; 6 months&#xD;
&#xD;
          -  At least one episode of documented ADHF during the previous 6 months&#xD;
&#xD;
          -  NYHA functional class III-IV&#xD;
&#xD;
          -  Circulating levels of NT-proBNP ≥ 800 ng/L.&#xD;
&#xD;
          -  Stable, optimized therapy for heart failure for at least 4 weeks prior to enrollment&#xD;
&#xD;
          -  Echocardiography performed within 3 months&#xD;
&#xD;
          -  Detectable ascites by ultrasound and/or computed tomography&#xD;
&#xD;
          -  Diuretic resistance defined as a daily dose of furosemide &gt; 80 mg, torsemide &gt; 40 mg&#xD;
             or bumetanide &gt; 2 mg&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Present or recurring systemic or local infection, such as peritonitis, urinary tract&#xD;
             infection, or abdominal skin infection.&#xD;
&#xD;
          -  Ongoing malignant disease with adverse prognosis&#xD;
&#xD;
          -  Evidence of firmly loculated peritoneal effusion.&#xD;
&#xD;
          -  Obstructive uropathy&#xD;
&#xD;
          -  Severely reduced renal function (S-Creatinine 300 mol/l) or end-stage renal disease&#xD;
             requiring dialysis&#xD;
&#xD;
          -  Severe liver disease (ASAT and/or ALAT and/or total bilirubin three times upper limit&#xD;
             of normal range laboratory values)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Requirement for intravenous inotropes&#xD;
&#xD;
          -  Acute coronary syndrome or any condition requiring emergency treatment&#xD;
&#xD;
          -  Heart disease requiring surgical intervention during the course of the study&#xD;
&#xD;
          -  Any other clinically significant disease that could be adversely affected by study&#xD;
             participation judged by the Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristjan Karason, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska University Hospital, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>May 21, 2009</study_first_submitted>
  <study_first_submitted_qc>May 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2009</study_first_posted>
  <last_update_submitted>December 16, 2011</last_update_submitted>
  <last_update_submitted_qc>December 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

